Vivos Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-13.58	-23.85	-20.29	-17.99	-11.75	-9.44
Depreciation & Amortization	0.62	0.67	0.73	0.72	0.75	0.61
Share-Based Compensation	1.11	2.4	2.68	2.17	1.99	1.57
Other Operating Activities	-0.09	1.19	1.14	3.49	2.68	0.94
Operating Cash Flow	-11.95	-19.59	-15.74	-5.68	-5.34	-5.31
Capital Expenditures	-0.85	-0.92	-2.4	-0.12	-0.18	-1.25
Acquisitions	0	0	-0.23	0	0.25	0.13
Change in Investments	0	0	0.01	0	0.01	0
Investing Cash Flow	-0.85	-0.92	-2.61	-0.12	0.09	-1.12
Share Issuance / Repurchase	12	0	27.93	22.29	1.25	6.45
Debt Issued / Paid	0	0	-0.03	1.19	3.73	-0.09
Other Financing Activities	-1.08	-	-3.74	0.06	-0.51	-1.1
Financing Cash Flow	10.92	0	24.17	23.54	4.47	5.25
Net Cash Flow	-1.88	-20.51	5.82	17.74	-0.79	-1.18
Free Cash Flow	-12.8	-20.51	-18.13	-5.8	-5.52	-6.56
Free Cash Flow Margin	-92.74%	-128.00%	-107.38%	-44.39%	-48.42%	-173.10%
Free Cash Flow Per Share	-10.50	-22.28	-21.35	-11.27	-11.18	-14.21

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).